Phase 3Active, not recruiting
Combination Gerotherapeutic Interventions for Healthspan Improvement
A Pilot Randomized Controlled Study of Combinatorial Gerotherapeutics for Healthspan Improvement
- Sponsor
- AgelessRx (Industry)
- Enrolment
- 30 planned
- Conditions
- Healthspan Improvement; Aging; Longevity
- Interventions
- Rapamycin; Naltrexone; Metformin; NAD+; GSH; Infinite Supplement; Placebo/control; B12; Intervention: Guided Meditation Program; Control: Podcast Listening Activity; Control: Standard Exercise Regimen; Intervention: Structured Exercise Program
- Ages
- adults, older adults
- Registry
- NCT07475546
From the registry
This study is a 90-day interventional, randomized, controlled pilot trial exploring multi-modal gerotherapies and their impact on longevity-related outcomes. In this proof-of-concept phase, a small sample size of up to 30 subjects (10 subjects in each arm) will be randomized into one of the three arms: 1) Control, 2) Multi-therapy (B12, Naltrexone, Metformin, and NAD+), or 4) Comprehensive Therapy (Rapamycin, Naltrexone, Metformin, B12, NAD+, GSH, and Infinite Supplement).
Primary outcomes
- Change in cardiorespiratory fitness measured by maximal oxygen uptake (VO₂ max)
- Change in cognitive performance measured by Creyos Cognitive Test composite score
- Change in systemic chronic inflammation measured by iAge index score
- Change in lean body mass measured by dual-energy X-ray absorptiometry (DEXA)